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Abstract 
Review of the cytogenetics abnormalities and genes 
involved in aggressive natural killer leukemia 
(ANKL) which is a rare form of leukemia mostly 
reported in East Asia. 
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Disease 
Aggressive natural killer leukemia (ANKL), 
previously known as "large granular lymphocyte 
(LGL) leukemia", is a rare neoplastic proliferation of 
mature natural killer (NK) cells described in the 
WHO classification of 2008 as a distinct entity 
separated it from T-cell LGL leukemia . The NK 
leukemic infiltration is predominantly systemic, 
involving the blood, bone marrow, liver, spleen, and 
less frequently, lymph nodes. ANKL has a rapidly 
fatal clinical course with a median survival of around 
2 months (Suzuki et al, 2004). 
Phenotype/cell stem origin 
Morphologically, the leukemic NK cells are slightly 
larger than normal LGLs. There is an ample amount 
of pale or slightly basophilic cytoplasm containing 
fine or coarse azurophilic granules. Bone marrow 
shows massive or focal infiltration by NK leukemic 
cells that can be intermingled reactive histiocytes 
with hemophagocytosis. In tissue sections, NK cells 
show diffuse or patchy destructive infiltrate. 
Necrosis, apoptosis, angioinvasion, and 
angiodestruction are common findings.  
It is believed that ANKL originates from mature NK 
cells.  The neoplastic NK cells are typically CD2+, 
surface CD3-, cytoplasmic CD3ε +, CD56+, and 
EBV+ with germline configuration of T-cell receptor 
(TCR) and immunoglobulin (Ig) genes. The 
exclusive expression of CD2 and CD56 and the 
absence of CD3 and TCRs in ANKL reflect its NK-
cell origin.  
A high expression rate of CD16 (75%) is also 
characteristic of ANKL (Li C et al 2014). CD16 is 
usually not expressed in other NK neoplasms, 
suggesting that CD16 is a specific marker for 
ANKL. Cases of ANKL are also positive for 
cytotoxic molecules and found to have high serum 
levels of CXCR1, CCR5 and soluble Fas ligand, 
suggesting that the chemokine system plays an 
important role in the systemic infiltration of NK 
leukemic cells and liver dysfunction (Makishima H 
et al, 2007). 
Etiology 
ANKL is almost always associated with Epstein-
Barr virus (EBV) infection. EBV plays a role in the 
pathobiology of ANKL and is considered 
responsible for its aggressive clinical features. 
Epidemiology 
This rare leukemia has a distinct geographic 
distribution with the most prevalence among East 
Asian populations. A fewer than 200 cases have been 
described in the literature, as a small series or single 
case report.  
The disease most commonly affects young to middle 
aged adults with a median age of 40 years. Both 
sexes are affected with a slight male predominance 
(Lima, M 2013; Zhang et al 2014). 
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Clinics 
Patients usually present extremely ill with high 
fever, significant weight loss, cytopenia, jaundice 
and abnormal liver function.  Hepatosplenomegaly is 
often massive accompanied by lymphadenopathy 
but less commonly skin lesions. Involvement of the 
gastrointestinal tract is present in many patients, and 
infiltration of leukemic NK cells into the 
cerebrospinal and peritoneal fluids, with clinical 
ascites, has been reported. The hemophagocytic 
syndrome is frequent at diagnosis or during the 
disease course, resulting from uncontrolled 
monocyte/macrophage activation in response to 
cytokines produced by the neoplastic NK-cells. 
Despite treatment, ANKL is rapidly progressive 
disease and most patients die within few weeks from 
disseminated intravascular coagulation and multi-
organ failure (Liang and Graham 2008; Lima, 2013). 
Treatment 
ANKL is refractory to the available chemotherapies. 
L-asparaginase containing chemotherapy regimen 
followed by allogeneic stem cell transplantation 
appears to slightly prolong overall survival, but 
relapse is almost inevitable (Ishida F, 2012). 
Prognosis 
ANKL is a dismal disease with an almost uniform 
mortality. Survival is measured in days to weeks. 
The overall median survival is less than 2 months. 
Cytogenetics 
Cytogenetics morphological 
Cytogenetic studies on ANKL are limited due to 
rarity of disease, and small samples marked with 
necrosis and mingled with inflammatory cells. 
Despite that, several studies have been reported 
some of them using comparative genomic 
hybridization (CGH) and loss of heterozygosity 
(LOH) techniques (Siu L et al 1999; Ohshima et al 
2002). Chromosome abnormalities are found in 
approximately 75% of cases including 
pseudodiploidy (57%), hyperdiploidy (30%), and 
hypodiploidy (13%). Although no disease-specific 
translocation(s) have not been identified, a complex 
karyotype with unbalanced rearrangements is found 
in most cases. Deletion of 6q appears to be the most 
frequent. Other recurrent abnormalities include  +X, 
i(1q), dup(1q), i(7q), +8, del(13q), del(17p), i(17q), 
and 11q23 rearrangement (Wong K, 1999; 
Nazarullah et al 2015).  Deletion of 17p/ TP53 was 
confirmed in at least one case with add(17p).  
Nakashima et al performed BAC-array CGH on 10 
cases of ANKL to detect genomic imbalances across 
the whole genome; the recurrent regions 
characteristic of this leukemia, were gain of 
chromosome 1q23-q31 and loss of 7p15.-p22 and 
17p13 (Nakashima et al, 2005).  Further 
investigation by the same group using oligo-array 
CGH combined with  gene-expression profiling of  
32 clinical samples and 7 cell lines  were used in an 
effort to delineate the molecular pathogenesis 
involved NK neoplasms (Karube K et al 2011). The 
gains of 1q31.2-44, 7q11.22-36.3, 16p13.3 and 
11p15.5, and the losses of 6q16.1-27 and 7p15.3-
22.2, were found in more than 8 cases (20%). 
Genes involved and 
proteins 
Note 
Karube at al found that  the 6q21 region 
encompassing POPDC3, PREP, PRDM1, ATG5, 
AIM1, LACE1, and FOXO3 was the most frequently 
deleted region of the whole genome. Both FOXO3 
and PRDM1expression were down-regulated in 
most NK-cell neoplasms compared with normal NK 
normal cells. The seven candidate genes were 
transduced into NK cell lines and forced re-
expression was induced. Re-expression of FOXO3 
and PRDM1 in NK cell lines suppressed cellular 
proliferation, but this was not the case after re-
expression of the other genes. Therefore, PRDM1 
and FOXO3 are considered to be tumor suppressor 
genes play an important role in the pathogenesis of 
NK-cell neoplasms (Karube K et al 2011).  
Yamanaka, et al study showed that dysregulation of 
microRNAs (miRNAs) has a significant role in the 
pathogenesis of NK-cell neoplasms. They 
demonstrated overexpression of two miRNA " 
MIR21and MIR155" in NK-cell 
lymphoma/leukemia primary specimens and cell 
lines. These two miRNAs act through PTEN and 
INPP5D (SHIP1), respectively, to regulate AKT1, a 
serine-threonine kinase involved in cell survival and 
proliferation. No translocations or genomic 
amplifications of the miR-2/17q23 or miR-
155/12q21 locus have been identified in NK 
neoplasms. Recent reports suggest that EBV 
infection can lead directly to up-regulation of miR-
21 and miR-155 which might be the first-hit genetic 
alterations in NK-cell pathogenesis. Finally, they 
proposed targeting miR-21 and/or miR-155 may 
represent a useful approach to treating NK-cell 
lymphoma/ leukemia (Yamanaka, et al, 2009). 
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